Dr. Reddy’s Laboratories Ltd (RDY) Plans Dividend of $0.29

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) announced a dividend on Tuesday, June 6th, NASDAQ reports. Shareholders of record on Monday, July 17th will be paid a dividend of 0.29 per share on Monday, July 17th. The ex-dividend date is Thursday, July 13th.

Dr. Reddy’s Laboratories has increased its dividend payment by an average of 7.4% per year over the last three years. Dr. Reddy’s Laboratories has a dividend payout ratio of 18.4% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Dr. Reddy’s Laboratories to earn $1.81 per share next year, which means the company should continue to be able to cover its $0.29 annual dividend with an expected future payout ratio of 16.0%.

Shares of Dr. Reddy’s Laboratories (RDY) traded down 4.19% during mid-day trading on Friday, reaching $34.57. 704,387 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $41.13 and its 200 day moving average price is $41.55. The company has a market cap of $5.73 billion, a PE ratio of 32.49 and a beta of 0.33. Dr. Reddy’s Laboratories has a 52-week low of $34.52 and a 52-week high of $50.10.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by BBNS and is owned by of BBNS. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://baseballnewssource.com/markets/dr-reddys-laboratories-ltd-rdy-to-go-ex-dividend-on-july-13th-updated-updated-updated/1180008.html.

A number of research analysts recently commented on the company. BidaskClub cut Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a report on Monday, July 31st. CLSA cut Dr. Reddy’s Laboratories from an “underperform” rating to a “sell” rating in a report on Friday, July 28th. Zacks Investment Research raised Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, July 14th. Finally, Deutsche Bank AG raised Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a report on Monday, May 15th. Two investment analysts have rated the stock with a sell rating and two have given a hold rating to the company. Dr. Reddy’s Laboratories currently has a consensus rating of “Hold”.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Receive News & Ratings for Dr. Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd and related companies with our FREE daily email newsletter.

 


Latest News

Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets


Leave a Reply

 
© 2006-2017 BBNS.